Similar articles

• Analgesics for the treatment of pain in children.

  Birenbaum D, Mattison DR. Birenbaum D, et al. N Engl J Med. 2003 Mar 6;348(10):959-60; author 959-60. doi: 10.1056/NEJM200303063481020. N Engl J Med. 2003. PMID: 12621144 No abstract available.
• Members of new FDA board tied to industry.

  Finkelstein JB. Finkelstein JB. J Natl Cancer Inst. 2008 Mar 5;100(5):296-7. doi: 10.1093/jnci/djn051. Epub 2008 Feb 26. J Natl Cancer Inst. 2008. PMID: 18314467 No abstract available.
• Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.

  Woodcock J. Woodcock J. Drug Discov Today. 2004 Jul 1;9(13):548-50. doi: 10.1016/S1359-6446(04)03160-5. Drug Discov Today. 2004. PMID: 15203087
• Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).

  Weaver J, Grenade LL, Kwon H, Avigan M. Weaver J, et al. Dermatol Ther. 2009 May-Jun;22(3):204-15. doi: 10.1111/j.1529-8019.2009.01233.x. Dermatol Ther. 2009. PMID: 19453344 Review.
• Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.

  Ball R, Horne D, Izurieta H, Sutherland A, Walderhaug M, Hsu H. Ball R, et al. Pediatrics. 2011 May;127 Suppl 1:S31-8. doi: 10.1542/peds.2010-1722F. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502249 Review.